TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00830999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive energy balance
Description: Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy balance with exercise
Description: Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative energy balance
Description: Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative energy balance with exercise
Description: Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy balance
Description: Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy balance
Description: Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy balance
Description: Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy balance
Description: Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
Study: NCT05024435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant Administration
Description: Laryngoscopy, intratracheal catheter placement and surfactant administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant Administration
Description: Laryngoscopy, intratracheal catheter placement and surfactant administration
Study: NCT03929185

Intervention type: DIAGNOSTIC_TEST
Intervention: blood analysis with SCENT B1
Description: analyze blood samples with chemoresistive sensors

Intervention type: DIAGNOSTIC_TEST
Intervention: blood analysis with SCENT B1
Description: analyze blood samples with chemoresistive sensors

Intervention type: DIAGNOSTIC_TEST
Intervention: tissue analysis with SCENT B1
Description: analyze tumor biopsies collected during surgery with chemoresistive sensors
Study: NCT03285802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg will be taken daily q 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg daily q 28 days
Study: NCT00702702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg
Description: Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 50 mg
Description: Proellex 50 mg, 2 - 25 mg capsules daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 capsules daily for 3 months
Study: NCT00984477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5122
Description: A single dose of oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5122
Description: A single dose of oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5122
Description: A single intravenous infusion
Study: NCT00953667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Niacin, Extended Release Niacin, Endotoxin
Description: Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
Study: NCT00823251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IlluminOss device
Description: The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
Study: NCT03011788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely Oral Solution
Description: Bowel purge prior to,colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely Oral Solution
Description: Bowel purge prior to,colonoscopy
Study: NCT01885156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin 1% Cream
Description: Topically applied once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topically applied once a day
Study: NCT02241148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500mg
Description: 500 mg, tablets every 8 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Taping will be changed every week.
Study: NCT03117231

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
Study: NCT01157676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cystectomy
Description: Standard of care removal of urinary bladder.
Study: NCT02663011

Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.

Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.

Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.

Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.

Intervention type: OTHER
Intervention: Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin
Description: To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation.
Study: NCT03212118

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU-0)
Description: The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured talks (TAU-2)
Description: Two structured talks (not including elements from motivational interviewing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing (MI)
Description: Two structured talks (must have a valid motivational interviewing content).
Study: NCT00405080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 (Casopitant) oral tablets
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 (Casopitant) oral tablets
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin oral capsules
Description: Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Study: NCT04034706

Intervention type: OTHER
Intervention: DEXA
Description: DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.

Intervention type: OTHER
Intervention: DEXA
Description: DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.

Intervention type: OTHER
Intervention: Magnetic Resonance (MR) Assessment of the Abdomen
Description: Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.

Intervention type: OTHER
Intervention: Magnetic Resonance (MR) Assessment of the Abdomen
Description: Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.

Intervention type: OTHER
Intervention: MR assessment of Whole Body Fat
Description: Volumetric measurement of fat, muscle and bone

Intervention type: OTHER
Intervention: MR assessment of Whole Body Fat
Description: Volumetric measurement of fat, muscle and bone

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: 0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: 0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
Study: NCT03782233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
Description: 50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
Study: NCT01157676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted radical cystectomy
Description: Standard of care removal of urinary bladder using DaVinci robot.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DaVinci robot
Description: DaVinci robotic surgical system.
Study: NCT03620916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days in the postoperative period
Study: NCT03782233

Intervention type: DRUG
Group type: OTHER
Intervention: A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).
Description: 33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
Study: NCT01814527

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid
Description: 5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules that are identical to the treatment.
Study: NCT03833492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion without the use of submucosal injection.
Study: NCT01715168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL/CAELYX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-0918
Study: NCT04338672

Intervention type: OTHER
Intervention: COVID-19 Pandemic
Description: Exposure: the novel coronavirus disease (Covid-19) outbreak
Study: NCT00343265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone gel
Description: Vaginal gel once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: once daily
Study: NCT03507036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound system
Description: Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
Study: NCT00468299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol and placebo
Description: Women in this group receive 800 mcg misoprostol plus a placebo
Study: NCT04496531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Neuromodulation Stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Portable Neuromodulation Stimulator
Study: NCT00468299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
Study: NCT00669890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: (Unrelated Donors only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: GVHD Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: GVHD Prophylaxis
Study: NCT01562080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus
Description: one tablet per day during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day during 12 weeks
Study: NCT03125226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Hydrogel
Description: Given TracelT hydrogel via injection
Study: NCT03332459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Study: NCT02789059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle oxygenation
Description: Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
Study: NCT01021735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept or adalimumab
Description: etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1g x2 by IV infusion repeated every 5 months or more
Study: NCT02388581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
Description: Anti-H. pylori Therapy
Study: NCT02205996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Humulin S)
Description: Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Humulin S)
Description: Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euglycaemic Hypoglycaemic Insulin clamp

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euglycaemic Hypoglycaemic Insulin clamp
Study: NCT04173806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook intervention
Description: The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Training:
Description: In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
Study: NCT00408850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15 mg per day for 6 weeks and 30 mg per day for further 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
Study: NCT04612725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo and Benralizumab
Description: 2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Study: NCT04068896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: NGM120 Dose 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo